Jasper Therapeutics Announces Key Briquilimab Updates

Jasper Therapeutics Inc: Company Overview

Jasper Therapeutics Inc (NASDAQ: JSPR) is a clinical-stage biotechnology company based in Redwood City, California. The company’s lead asset, briquilimab, is an aglycosylated monoclonal antibody that blocks stem cell factor from binding to the KIT (CD117) receptor. By inhibiting KIT signaling, briquilimab aims to deplete mast cells via apoptosis and address mast cell–driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma.

Corporate Structure

Founded by industry veterans and supported by leading academic collaborators, Jasper employs between 51 and 200 people. Its executive team includes Ronald Martell (CEO), Edwin Tucker, M.D. (Chief Medical Officer), Jeet Mahal (Chief Business Officer), and other leaders with experience in drug development and commercialization. A Scientific Advisory Board of experts in immunology and mast cell biology provides guidance on the company’s research programs.

Briquilimab by Guillaume Flandre

Recent Developments and News

• On June 3, 2025, Jasper announced that four abstracts on briquilimab were accepted for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress (Glasgow, June 13–16). Topics include:
– Initial SPOTLIGHT Phase 1b/2a dose-escalation results in adults with inducible urticaria
– Single-dose protection against epicutaneous allergen-induced dermatitis in humanized mice
– Updated Phase 1b/2a data demonstrating disease control in CSU patients
– Preclinical respiratory model results in allergen and smoke-exacerbated conditions

• On July 7, 2025, Jasper filed a Form 8-K with the SEC reporting material events under items 8.01 and 9.01. Earlier, on July 3, 2025, the company filed an 8-K under item 5.07. Details are available via the SEC’s XBRL viewer.

• In February 2024, Jasper completed an underwritten public offering of 3.9 million common shares at $12.95 per share, raising approximately $50 million in gross proceeds. Paul Hastings LLP served as legal advisor.

Financial and Strategic Analysis

As of July 7, 2025, JSPR shares closed at $2.39, representing a decrease of 64.70% over the comparable period, with a trading volume of 1,060,090 shares on the NASDAQ. The February 2024 equity raise strengthened the company’s cash position to support ongoing clinical trials. Strategically, Jasper is focused on advancing SPOTLIGHT Phase 1b/2a cohorts in CIndU and CSU, with upcoming data expected to inform regulatory planning and potential collaborations.

Market Position and Industry Context

Jasper operates in the immunology and inflammation sectors, targeting mast cell-mediated conditions. Briquilimab's mechanism, which blocks KIT signaling, differs from established H1-antihistamines and anti-IgE therapies. The company faces competition from both approved biologics and emerging pipeline candidates in dermatology and respiratory indications. Successful outcomes in clinical trials could position Jasper for potential partnerships or licensing agreements prior to regulatory submissions.

tl;dr

On June 3, 2025, four briquilimab abstracts were accepted for EAACI 2025 presentations, including SPOTLIGHT Phase 1b/2a data for CIndU and preclinical respiratory models. As of July 7, 2025, JSPR stock traded at $2.39 (–64.70%) with 1,060,090 shares exchanged. Jasper filed an 8-K on July 7, 2025 (items 8.01 and 9.01) and anticipates further data readouts from its SPOTLIGHT trial to guide clinical and regulatory activities.